Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Cardiovascular Disease Risk in End-Stage Renal Disease.
Feng-Jung YangChun-Yih HsiehKai-Hsiang ShuI-Yu ChenSzu-Yu PanYi-Fang ChuangYen-Ling ChiuWei-Shiung YangPublished in: Scientific reports (2020)
Plasma leucine-Rich α-2-glycoprotein 1 (LRG1) is an innovative biomarker for inflammation and angiogenesis. Many adverse pathophysiological changes including inflammation, atherosclerosis, and premature mortality is associated with End-stage renal disease (ESRD). However, whether levels of plasma LRG1 correlate with the co-morbidities of ESRD patients is unknown. Plasma LRG1 and high-sensitivity C-reactive protein (hsCRP) were analyzed by ELISA in 169 hemodialysis patients from the Immunity in ESRD (iESRD) study. Patient demographics and comorbidities at the time of enrollment were recorded. Peripheral blood monocyte and T cell subsets were assessed by multicolor flow cytometry. In the univariate analysis, a higher level of LRG1 was associated with the presence of cardiovascular disease (CVD) and peripheral arterial occlusive disease (PAOD). In multivariate logistic regression models, higher LRG1 tertile was significantly associated with PAOD (odds ratio = 3.49) and CVD (odds ratio = 1.65), but not with coronary artery disease, history of myocardial infarction, or stroke after adjusting for gender, diabetes, hemoglobin, albumin, calcium-phosphate product, and level of hsCRP. In addition, the level of LRG1 had a positive correlation with IL-6, hsCRP, and also more advanced T cell differentiation. The association suggests that LRG1 participates in the progression of atherosclerosis by inducing inflammation. Therefore, the role of LRG1 in coexisting inflammatory response should be further investigated in the pathogenesis of cardiovascular morbidity and mortality in patients with ESRD.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- cardiovascular disease
- peripheral blood
- flow cytometry
- oxidative stress
- inflammatory response
- coronary artery disease
- type diabetes
- cardiovascular events
- left ventricular
- percutaneous coronary intervention
- health insurance
- metabolic syndrome
- toll like receptor
- cardiovascular risk factors
- mass spectrometry
- vascular endothelial growth factor
- adipose tissue
- immune response
- aortic valve
- glycemic control
- data analysis
- acute coronary syndrome
- coronary artery bypass grafting
- red blood cell